T Zuberbier

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases
    Torsten Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Germany
    J Dtsch Dermatol Ges 10:879-85. 2012
  2. ncbi Chronic urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Germany
    Curr Allergy Asthma Rep 12:267-72. 2012
  3. ncbi Density-equalizing mapping and scientometric benchmarking of European allergy research
    Cristian Scutaru
    Institute of Occupational Medicine, Charite Universitatsmedizin Berlin, Free University Berlin and Humboldt University Berlin, Berlin, Germany
    J Occup Med Toxicol 5:2. 2010
  4. ncbi Patient perspectives on the management of atopic dermatitis
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergy Centre Charité, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, D 10117 Berlin, Germany
    J Allergy Clin Immunol 118:226-32. 2006
  5. ncbi Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease
    T Zuberbier
    Department of Dermatology and Allergy, Allergy Centre Charité, Berlin, Germany
    J Eur Acad Dermatol Venereol 22:718-21. 2008
  6. ncbi Urticaria: current opinions about etiology, diagnosis and therapy
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin, Berlin, Germany
    Acta Derm Venereol 87:196-205. 2007
  7. ncbi [Diagnosis of allergies]
    Torsten Zuberbier
    Klinik für Dermatologie und Allergologie, Charite Campus Mitte, Berlin
    Z Arztl Fortbild Qualitatssich 97:446-51. 2003
  8. ncbi Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin, Berlin, Germany
    J Eur Acad Dermatol Venereol 26:9-18. 2012
  9. ncbi Antihistamines in the treatment of urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Berlin, Germany
    Adv Exp Med Biol 709:67-72. 2011
  10. ncbi Antihistamines in the treatment of urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Charitiplatz 1, D 10117 Berlin
    Adv Exp Med Biol 709:67-72. 2010

Detail Information

Publications107 found, 100 shown here

  1. ncbi Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases
    Torsten Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Germany
    J Dtsch Dermatol Ges 10:879-85. 2012
    ..The success of its use depends on correct indications, use of standardized extracts and monitoring the therapeutic response...
  2. ncbi Chronic urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Germany
    Curr Allergy Asthma Rep 12:267-72. 2012
    ..Alternative treatments for the afflicted who do not respond to antihistamine-treatment are also available but are not approved for use on urticaria...
  3. ncbi Density-equalizing mapping and scientometric benchmarking of European allergy research
    Cristian Scutaru
    Institute of Occupational Medicine, Charite Universitatsmedizin Berlin, Free University Berlin and Humboldt University Berlin, Berlin, Germany
    J Occup Med Toxicol 5:2. 2010
    ..Three different meetings of the European Academy of Allergy and Clinical Immunology were analysed for contributions and an increase in both the amount of research and networks was found...
  4. ncbi Patient perspectives on the management of atopic dermatitis
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergy Centre Charité, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, D 10117 Berlin, Germany
    J Allergy Clin Immunol 118:226-32. 2006
    ..Atopic dermatitis (AD) is increasingly common, with a point prevalence of more than 30% in some countries, and is characterized by visible skin lesions and intense itching...
  5. ncbi Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease
    T Zuberbier
    Department of Dermatology and Allergy, Allergy Centre Charité, Berlin, Germany
    J Eur Acad Dermatol Venereol 22:718-21. 2008
    ....
  6. ncbi Urticaria: current opinions about etiology, diagnosis and therapy
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin, Berlin, Germany
    Acta Derm Venereol 87:196-205. 2007
    ..g. allergic rhinitis. The current guidelines therefore suggest increasing the dosage up to four-fold, whereas alternative treatments should be reserved as add-on therapy for unresponsive patients...
  7. ncbi [Diagnosis of allergies]
    Torsten Zuberbier
    Klinik für Dermatologie und Allergologie, Charite Campus Mitte, Berlin
    Z Arztl Fortbild Qualitatssich 97:446-51. 2003
    ....
  8. ncbi Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin, Berlin, Germany
    J Eur Acad Dermatol Venereol 26:9-18. 2012
    ..Given the fact that only few controlled studies have assessed the efficacy and safety of high-dose non-sedating antihistamines in CU, patient safety should be a key consideration when choosing a specific antihistamine...
  9. ncbi Antihistamines in the treatment of urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Berlin, Germany
    Adv Exp Med Biol 709:67-72. 2011
    ..g., allergic rhinitis. Therefore, the current guidelines suggest increasing the dosage up to fourfold, whereas alternative treatments should be reserved as add-on therapy for unresponsive patients...
  10. ncbi Antihistamines in the treatment of urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Charitiplatz 1, D 10117 Berlin
    Adv Exp Med Biol 709:67-72. 2010
    ..g., allergic rhinitis. Therefore, the current guidelines suggest increasing the dosage up to fourfold, whereas alternative treatments should be reserved as add-on therapy for unresponsive patients...
  11. ncbi GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 65:1525-30. 2010
    ..The recommendations cover patient selection, allergen extract to be used, route of administration of SIT (in particular, sublingual and subcutaneous immunotherapy), and necessary precautions to be followed in using SIT...
  12. ncbi [National and international information sources for medical personnel and patients]
    T Zuberbier
    Klinik fur Dermatologie, Allergologie und Venerologie, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117 Berlin, Germany
    Hautarzt 58:318-20. 2007
    ..The Internet sites listed in this article provide patients and physicians with extensive information on urticaria, mastocytosis and allergies in general. They are user-friendly and enable patients to easily acquire information...
  13. ncbi Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis
    Torsten Zuberbier
    Department of Dermatology and Allergy, Allergy Centre Charité, Berlin, Germany
    Dermatology 215:325-30. 2007
    ..To investigate if pimecrolimus cream 1% reduces the need for steroids in the long-term management of severe pediatric atopic dermatitis (AD)...
  14. ncbi Epidemiology of urticaria: a representative cross-sectional population survey
    T Zuberbier
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Germany
    Clin Exp Dermatol 35:869-73. 2010
    ..To investigate the prevalence of urticaria with a focus on chronic urticaria (CU) in a general German population...
  15. ncbi Effect of granulocyte macrophage colony-stimulating factor in a patient with benign systemic mastocytosis
    T Zuberbier
    Department of Dermatology and Allergy, Charite, Humboldt University, 13344 Berlin, Germany
    Br J Dermatol 145:661-6. 2001
    ..These findings and the observed adverse clinical effects in the present patient make it unlikely that GM-CSF monotherapy will be beneficial for the treatment of mastocytosis...
  16. ncbi Management of urticaria: a consensus report
    T Zuberbier
    Department of Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany
    J Investig Dermatol Symp Proc 6:128-31. 2001
    ..Immunosuppressive drugs like cyclosporine A and corticosteroids should not be used long term due to undesirable side-effects...
  17. ncbi The role of allergens and pseudoallergens in urticaria
    T Zuberbier
    Department of Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany
    J Investig Dermatol Symp Proc 6:132-4. 2001
    ..Double-blind, placebo-controlled challenge tests have shown that artificial food additives are not only to blame, with the majority of reactions being traced back to naturally occuring pseudoallergens in food...
  18. ncbi Definition, classification, and routine diagnosis of urticaria: a consensus report
    T Zuberbier
    Department of Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany
    J Investig Dermatol Symp Proc 6:123-7. 2001
    ..In addition, this consensus report provides a guideline for diagnostic procedures in different subtypes of urticaria...
  19. ncbi Food allergy and non-allergic food hypersensitivity in children and adolescents
    C C Roehr
    Department of Pediatric Pneumology and Immunology, University Hospital Charit, Humboldt University, Berlin, Germany
    Clin Exp Allergy 34:1534-41. 2004
    ..Severe IgE-mediated FA was observed in individuals with pre-existing atopic disease, who should be fully investigated for clinically relevant FA...
  20. ncbi EAACI/GA2LEN/EDF guideline: management of urticaria
    T Zuberbier
    Department of Dermatology and Allergy, , Berlin, Germany
    Allergy 61:321-31. 2006
    ..This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS)...
  21. ncbi GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe
    L M Heinzerling
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 64:1498-506. 2009
    ..Thus, it has been difficult to compare results from different centres or studies across Europe. It was, therefore, crucial to standardize and harmonize procedures in allergy diagnosis and treatment within Europe...
  22. ncbi GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe
    G J Burbach
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 64:1507-15. 2009
    ....
  23. ncbi Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg
    M Magerl
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charité Universitätsmedzin Berlin, Berlin, Germany
    Clin Exp Dermatol 34:e137-40. 2009
    ..Weals, pruritus and burning were greatly reduced for most subjects. This pilot study suggests that ebastine is safe and effective in preventing the symptoms of DU and should be tested on a larger scale...
  24. ncbi EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 64:1427-43. 2009
    ..Corticosteroids are not recommended for long-term treatment due to their unavoidable severe adverse effects. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS)...
  25. ncbi Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus
    R Vieira Dos Santos
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Berlin, Germany
    Br J Dermatol 162:674-6. 2010
    ..Although mast cell stabilization was initially considered as its mechanism of action, anti-inflammatory actions and modulation of sensory nerve function have also been suggested...
  26. ncbi Mast cell and myeloid marker expression during early in vitro mast cell differentiation from human peripheral blood mononuclear cells
    P Welker
    Department of Dermatology, Humboldt University, Brelin, Germany
    J Invest Dermatol 114:44-50. 2000
    ..Keywords: c-kit/FcepsilonRI/SCF/tryptase...
  27. ncbi Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report
    M Maurer
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 66:317-30. 2011
    ..Consequently, there is a great need for new therapeutic strategies...
  28. ncbi GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells
    P Welker
    Department of Dermatology and Allergy, Humboldt University, Berlin, Germany
    Arch Dermatol Res 293:249-58. 2001
    ..GM-CSF may therefore function as a regulatory factor in mast cell growth and differentiation under normal and pathological conditions...
  29. ncbi EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 64:1417-26. 2009
    ..This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS)...
  30. ncbi Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial
    M Magerl
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 65:78-83. 2010
    ..Eliminating pseudoallergens from the diet can reduce symptom severity and improve patient quality of life...
  31. ncbi [Therapeutic alternatives for antihistamine-refractory urticaria]
    M Maurer
    Klinik fur Dermatologie, Venerologie und Allergologie, Allergie Centrum Charité Universitätsmedizin Berlin, Chariteplatz 1, 10117, Berlin
    Hautarzt 61:765-9. 2010
    ..If the patient does not respond to this combination therapy, cyclosporin A, dapsone, or omalizumab should be administered...
  32. ncbi Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria
    A Młynek
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, 10117 Berlin, Germany
    Br J Dermatol 162:198-200. 2010
    ..Conclusions These findings indicate that temperature threshold measurements may be used for assessing disease severity and activity as well as the efficacy of therapeutic measures including novel treatment approaches for cold urticaria...
  33. ncbi EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria
    T Zuberbier
    Department of Dermatology and Allergy, , Berlin, Germany
    Allergy 61:316-20. 2006
    ..This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and was formally approved by the European Union of Medical Specialists (UEMS)...
  34. ncbi The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
    T Zuberbier
    Department of Dermatology and Allergy, , Humboldt University Berlin, Germany
    J Allergy Clin Immunol 108:275-80. 2001
    ..Pimecrolimus might thus be expected to be effective in the treatment of mast cell-- and basophil-dependent diseases...
  35. ncbi Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study
    K Krause
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 67:943-50. 2012
    ..This study evaluated the effects of the interleukin-1 antagonist rilonacept on the clinical signs and symptoms of SchS...
  36. ncbi Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper
    M K Church
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Germany
    Allergy 65:459-66. 2010
    ....
  37. ncbi Risk factors of adverse reactions to food in German adults
    S Soost
    Department of Dermatology and Allergy, Allergy Center Charité, Universitatsmedizin Berlin, Germany
    Clin Exp Allergy 39:1036-44. 2009
    ..Allergic diseases have been increasing during the last decades. Previous studies suggest an impact of a variety of risk factors on the prevalence of food hypersensitivity...
  38. ncbi Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance
    M Worm
    Humboldt University, Department of Dermatology and Allergy, Charite Campus Mitte, Schumannstr 20 21, D 10117 Berlin, Germany
    Clin Exp Allergy 31:265-73. 2001
    ..These findings indicate that single food additives as aggravating factors in AD patients may trigger the disease through increased sLT production as a pathophysiological mechanism...
  39. ncbi Impact of native, heat-processed and encapsulated hazelnuts on the allergic response in hazelnut-allergic patients
    M Worm
    Department of Dermatology and Allergy, Allergy Centrum Charité Campus Mitte, Universitaetsmedizin Berlin, Germany
    Clin Exp Allergy 39:159-66. 2009
    ..Pollen-associated food allergy is common. However, systemic reactions or even life-threatening anaphylaxis are rare...
  40. ncbi A loose-fit coculture of activated keratinocytes and dendritic cell-related cells for prediction of sensitizing potential
    M Schreiner
    Institute of Molecular Biology and Bioinformatics, Charite, Berlin, Germany
    Allergy 62:1419-28. 2007
    ..Donor-variance is negligible. This in vitro assay based on a loose-fit coculture is a reasonable approach to screen for the sensitizing potential of xenobiotics and might partially replace the LLNA and other animal tests...
  41. ncbi Acquired cold urticaria symptoms can be safely prevented by ebastine
    M Magerl
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 62:1465-8. 2007
    ..It has a profound impact on patient quality of life. Second-generation antihistamines are recommended as the first-line treatment, but to date only a few have been scientifically tested for this condition...
  42. ncbi Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice
    M Babina
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Exp Allergy 40:1256-65. 2010
    ..We hypothesized that TX might inhibit type I allergic reactions, which are also characterized by deviations in humoral immunity...
  43. ncbi [Urticaria. New developments and perspectives]
    B M Henz
    Klinik fur Dermatologie, Venerologie und Allergologie mit Asthmapoliklinik, Charite, Humboldt Universitat zu Berlin
    Hautarzt 51:302-8. 2000
    ..On the basis of recent findings, autoantibodies must be viewed mostly as secondary rather than causative in chronic urticaria...
  44. ncbi Prevalence of adverse reactions to food in Germany - a population study
    T Zuberbier
    Department of Dermatology and Allergy, University Hospital Charit, Humboldt University, Germany
    Allergy 59:338-45. 2004
    ..The data also show that an individualized stepwise approach including provocation tests is mandatory to confirm the diagnosis...
  45. ncbi A combination of wheat flour, ethanol and food additives inducing FDEIA
    E-M Fiedler
    Department of Dermatology and Allergy, University Clinic Charit, Schumannstrasse 20/21, D-10117 Berlin, Germany
    Allergy 57:1090-1. 2002
  46. ncbi A new dendritic cell type suitable as sentinel of contact allergens
    Maximilian Schreiner
    Institute of Molecular Biology and Bioinformatics, Charite, Berlin, Germany
    Toxicology 249:146-52. 2008
    ..Animal-based assays do not meet this requirement. The LCSA provides dose-response information, thereby allowing prediction of the relative ability of a substance to induce sensitization...
  47. ncbi Decreased cutaneous expression of stem cell factor and of the p75NGF receptor in urticaria
    B Hermes
    Department of Dermatology, Prenzlauer Berg Hospital, Berlin, Germany
    Br J Dermatol 148:411-7. 2003
    ..Serum NGF has however, been reported to be increased in urticaria...
  48. ncbi Ethanol as a cause of hypersensitivity reactions to alcoholic beverages
    I Ehlers
    Department of Dermatology and Allergy, Charit, Hamboldt-University, Berlin, Germany
    Clin Exp Allergy 32:1231-5. 2002
    ..Increased sulfidoleukotriene production was determined in some patients, but is no reliable predictor. Therefore oral provocation tests remain indispensable in making the diagnosis of ethanol hypersensitivity...
  49. ncbi Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients
    M Maurer
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Chariteplatz 1, D 10117 Berlin, Germany
    Br J Dermatol 160:633-41. 2009
    ..Very little is known about the health behaviour, symptom patterns or unmet treatment needs of patients with CU...
  50. ncbi Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy
    M Metz
    Department of Dermatology and Allergy, , , Berlin, Germany
    Allergy 63:247-9. 2008
  51. ncbi Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study
    T Zuberbier
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Germany
    Allergy 65:516-28. 2010
    ..The aim of this study was to compare the clinical efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg and placebo in CU patients with moderate-to-severe symptoms...
  52. ncbi Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production
    M Milovanovic
    Department of Dermatology and Allergy, Allergy Center Charité, CCM, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Exp Allergy 39:671-8. 2009
    ..The induction of antigen-specific IL-10 secreting T cells is discussed as an important mechanism during specific immunotherapy. By contrast the presence and function of B cell-derived IL-10 is not well defined yet...
  53. ncbi The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings
    A Młynek
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Germany
    Allergy 64:927-36. 2009
    ..The aim of this work was to generate and validate a German version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q(2)oL) and to provide reference assessments of QoL...
  54. ncbi Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study
    K Weller
    Department of Dermatology and Allergy, Allergy Centrum Charité, Charite Universitatsmedizin, Berlin, Germany
    J Eur Acad Dermatol Venereol 27:43-50. 2013
    ..Recently, the updated EAACI/GA(2) LEN/EDF/WAO guidelines for urticaria have been published...
  55. ncbi Gene expression and regulation of transcription factor activator protein-2 alpha in human mast cells
    P Welker
    Department of Dermatology and Allergy, , Free University and Humboldt-University, Berlin, Germany
    Allergy 60:1046-52. 2005
    ..CONCLUSIONS: These findings suggest a continuous activation of AP-2alpha in mastocytomas and mast cell leukemia and its transient upregulation during c-Kit dependent early steps of normal mast cell differentiation...
  56. ncbi Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network
    L Heinzerling
    Department of Dermatology and Allergy, , Berlin, Germany
    Allergy 60:1287-300. 2005
    ..This overview may serve as reference for the practising doctor and suggests a GA(2)LEN Pan-European core SPT panel...
  57. ncbi Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis
    S Dölle
    Charite Universitatsmedizin Berlin, Department of Dermatology and Allergology, Berlin, Germany
    Allergy 65:1158-65. 2010
    ..With this controlled clinical study, the clinical and immunomodulatory efficacy of miltefosine was investigated in patients with AD in comparison with a topical corticosteroid treatment...
  58. ncbi Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation
    M Maurer
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin, Berlin, Germany
    Allergy 64:581-8. 2009
    ..It has been shown to have substantial impact on patient quality-of-life, but little else is known about patient perspectives on CU and its treatment...
  59. ncbi Sugar is not an aggravating factor in atopic dermatitis
    I Ehlers
    Department of Dermatology and Allergy, Charite, Humboldt University, Berlin, Germany
    Acta Derm Venereol 81:282-4. 2001
    ..From these results, we conclude that sugar is not an aggravating factor in atopic dermatitis, which contradicts the view of many patients and underlines the importance of evidence-based medicine in the guidance of patients...
  60. ncbi Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor
    P Welker
    Department of Dermatology, Charite, Humboldt University, Berlin
    Scand J Immunol 49:495-500. 1999
    ....
  61. ncbi Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A
    Anne C Röver
    Department of Dermatology and Allergy, Charite, Humboldt University, Berlin
    J Investig Allergol Clin Immunol 12:227-34. 2002
    ..Whether these effects are a result of direct allergen action on the B cells or whether they are mediated by T cells and their clinical relevance remains to be elucidated...
  62. ncbi [Sublingual immunotherapy. Where are we now?]
    H Lee
    Allergie Centrum Charité, Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Berlin
    Hautarzt 62:467-74; quiz 475. 2011
    ..In particular the sublingual-swallow method (SLIT) has been proven to be effective and well-tolerated in large studies on grass pollen allergies and represents an additional effective route of administration in adults and children...
  63. ncbi [Current recommendations for the use of SCIT and SLIT]
    H Lee
    Allergie-Centrum-Charit, , Venerologie und Allergologie, , , 10117, Berlin, Deutschland
    Hautarzt 57:860-6. 2006
    ..The clinical symptoms and the age of the patients determine the route of application, choice of allergen extracts and the duration of treatment. Numerous products and protocols facilitate an individualised therapy...
  64. ncbi Insulin allergy: clinical manifestations and management strategies
    L Heinzerling
    Department of Dermatology and Allergy, Charite Universitatsmedizin, Berlin, Germany
    Allergy 63:148-55. 2008
    ..It can be managed well in close cooperation between the diabetologist and the allergologist. Specific immunotherapy is efficient and should be considered...
  65. ncbi Acquired cold urticaria: clinical picture and update on diagnosis and treatment
    F Siebenhaar
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Exp Dermatol 32:241-5. 2007
    ..This review gives an overview of the clinical picture, the differential diagnoses, diagnostic tests and the aetiology of ACU, and summarizes current and novel therapeutic options based on the current literature...
  66. ncbi Establishing a standardized quality management system for the European Health Network GA2LEN
    L Heinzerling
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 65:743-52. 2010
    ..Although some allergy centres adhere to internal quality criteria, the implementation of a standardized quality management system for allergy centres across Europe was lacking...
  67. ncbi Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey
    M Maurer
    Allergie Centrum Charité Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Member of GA 2 LEN Berlin, Germany
    Allergy 62:1057-63. 2007
    ..This study elucidates the reasons for this discrepancy from the patients' point of view...
  68. ncbi Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred
    N Haas
    Department of Dermatology and Allergy, Charit, , , Schumannstr. 20/21, D-10117 Berlin, Germany
    Br J Dermatol 151:99-104. 2004
    ..Microscopic features are similar to those observed in other types of urticaria...
  69. ncbi How to assess disease activity in patients with chronic urticaria?
    A Młynek
    Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Allergy 63:777-80. 2008
    ..e. the urticaria activity score (UAS), which combines daily wheal numbers and pruritus intensity. However, this UAS has never been formally tested for its suitability in assessing CU activity...
  70. ncbi Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy
    H Lee
    , , 10117 Berlin Germany
    Allergy 61:1237-8. 2006
  71. ncbi Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB
    Franziska Rompe
    Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Hypertension 55:924-31. 2010
    ..These data suggest that pharmacological AT(2) receptor stimulation may be an orally applicable future therapeutic approach in pathological settings requiring the reduction of interleukin 6 or inhibition of nuclear factor kappaB...
  72. ncbi Treatment strategies in urticaria
    Lucija Kröpfl
    Expert Opin Pharmacother 11:1445-50. 2010
    ..Many new therapies are available to patients with urticaria refractory to common therapies and it is important to consider second- and third-line therapies...
  73. ncbi Modern approaches to the diagnosis and treatment of cold contact urticaria
    Karoline Krause
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Berlin, Germany
    Curr Allergy Asthma Rep 10:243-9. 2010
    ..Standardizing cold provocation tests and further characterization of the natural course of CCU and its variants may lead to a better understanding of the disease-driving mechanisms...
  74. ncbi Classification of sensitizing and irritative potential in a combined in-vitro assay
    Reinhard Wanner
    Institute of Clinical Pharmacology and Toxicology, Charite, Berlin, Germany
    Toxicol Appl Pharmacol 245:211-8. 2010
    ....
  75. ncbi Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria
    Torsten Zuberbier
    Department of Dermatology and Allergy, Charit, Humboldt University, Germany
    J Allergy Clin Immunol 109:343-8. 2002
    ..Histamine, salicylate, and a direct mast-cell histamine release are not involved in this reactivity to naturally occurring pseudoallergens...
  76. ncbi Human mast cells in the neurohormonal network: expression of POMC, detection of precursor proteases, and evidence for IgE-dependent secretion of alpha-MSH
    Metin Artuc
    Department of Dermatology, Charite, Humboldt University, Berlin, Germany
    J Invest Dermatol 126:1976-81. 2006
    ..Moreover, IgE-dependent release of alpha-MSH suggests an immunomodulatory role of this neurohormone during inflammatory and allergic reactions of the skin...
  77. ncbi Sublingual immunotherapy
    Lucie Heinzerling
    Department of Dermatology and Allergy, Allergy Center Charit, Berlin, Germany
    J Dtsch Dermatol Ges 4:428-33; quiz 434-5. 2006
  78. ncbi Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells
    Magda Babina
    Department of Dermatology and Allergy, Universitatsmedizin Berlin, Berlin, Germany
    Exp Dermatol 15:530-7. 2006
    ..Interestingly, c-Kit regulation seems largely independent of the MC subtype...
  79. ncbi Comparative cytokine profile of human skin mast cells from two compartments--strong resemblance with monocytes at baseline but induction of IL-5 by IL-4 priming
    Magda Babina
    Department of Dermatology and Allergy, Charite, Universitäts Medizin, Berlin, Germany
    J Leukoc Biol 75:244-52. 2004
    ....
  80. ncbi Frequency of atopic dermatitis and relevance of food allergy in adults in Germany
    Margitta Worm
    Allergy Centre Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, D 10117 Berlin, Germany
    Acta Derm Venereol 86:119-22. 2006
    ..A non-selected AD patient cohort does not frequently suffer from clinically relevant pollen-associated food allergy...
  81. ncbi Exogenous histamine aggravates eczema in a subgroup of patients with atopic dermatitis
    Margitta Worm
    Department of Dermatology and Allergology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Acta Derm Venereol 89:52-6. 2009
    ..Plasma histamine and diamine oxidase activity were not associated with the clinical response to histamine...
  82. ncbi Long-term cultured human skin mast cells are suitable for pharmacological studies of anti-allergic drugs due to high responsiveness to FcεRI cross-linking
    Sven Guhl
    Department of Dermatology and Allergy, Charite Campus Mitte, Universitatsmedizin Berlin, Berlin, Germany
    Biosci Biotechnol Biochem 75:382-4. 2011
    ..In a proof-of-concept, we found that these cells are useful for pharmacological testing. Even a subtle inhibition of degranulation can be visualized. This model might prove valuable in tests of novel anti-allergic drugs...
  83. ncbi The transcription factor profile of human mast cells in comparison with monocytes and granulocytes
    M Babina
    Department of Dermatology and Allergy, University Hospital Charité Campus Mitte, Schumannstr 20 21, 10117, Berlin, Germany
    Cell Mol Life Sci 62:214-26. 2005
    ..In summary, mature human MCs can be characterized as C/EBPalpha(low), C/EBPvarepsilon-, PU.1(low), GATA-1(low), GATA-2+, SCL+, MITF(high)...
  84. ncbi Type I sensitization towards patent blue as a cause of anaphylaxis
    K Forschner
    Department of Dermatology and Allergy, Charit, Humboldt University, Schumannstrasse 20/21 D-10117, Berlin, Germany
    Allergy 58:457-8. 2003
  85. ncbi Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability
    S Buhner
    Department of Gastroenterology, Hepatology, and Endocrinology, , Berlin, Germany
    Allergy 59:1118-23. 2004
    ..The underlying mechanisms seem to be independent of H. pylori infection...
  86. ncbi Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells
    U Lippert
    Department of Dermatology, Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    J Immunol 161:2600-8. 1998
    ..These findings demonstrate for the first time the functional expression of both types of IL-8 receptors on human mast cells, suggesting a role for their ligands during mast cell activation and recruitment...
  87. ncbi Evidence for a restricted rather than generalized stimulatory response of skin-derived human mast cells to substance P
    Sven Guhl
    Department of Dermatology and Allergy, Charit, Campus Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany
    J Neuroimmunol 163:92-101. 2005
    ....
  88. ncbi Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells
    Markus Magerl
    Department of Dermatology and Allergy, Charite Universitatsmedizin, Berlin, Germany
    Exp Dermatol 17:427-35. 2008
    ..Although recent research has illuminated the role of MCs in bacterial infection, little is known about how non-pathogenic bacteria influence MC responses...
  89. ncbi Benzoyl peroxide as a cause of airborne contact dermatitis in an orthopaedic technician
    K Forschner
    Department of Dermatology and Allergy, Charit, Humboldt University Berlin, Germany
    Contact Dermatitis 47:241. 2002
  90. ncbi Allergen-mediated modulation of CD23 expression is interferon-gamma and interleukin-10 dependent in allergic and non-allergic individuals
    A C Roever
    Department of Dermatology and Allergy, , Humboldt University, Berlin, Germany
    Clin Exp Allergy 33:1568-75. 2003
    ....
  91. ncbi Role of adverse reactions to food in urticaria and exercise-induced anaphylaxis
    Sie-Uen Chong
    Department of Dermatology and Allergy, Charit, Humboldt University Berlin, Campus Mitte, Schumannstrasse 20/21, D-10117 Berlin, Germany
    Int Arch Allergy Immunol 129:19-26. 2002
    ..In specific FDEIA, an IgE-mediated food allergy causes symptoms only in combination with exercise. In the latter group, wheat is an important allergen...
  92. ncbi Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands
    Salima Mrabet-Dahbi
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Exp Dermatol 18:437-44. 2009
    ..e. tissue-residing cells, which most likely occurs during infection, can selectively raise a potent inflammatory or anti-inflammatory response, depending on TLRs which are engaged...
  93. ncbi High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study
    Frank Siebenhaar
    Allergie Centrum Charité, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Allergy Clin Immunol 123:672-9. 2009
    ..Prospective data supporting this recommendation are scant...
  94. ncbi Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent
    Frank Siebenhaar
    Department of Dermatology and Allergy, Allergie Centrum Charité, Charite Universitatsmedizin Berlin, Chariteplatz 1, D 10117 Berlin, Germany
    Am J Pathol 170:1910-6. 2007
    ..These findings demonstrate for the first time that activated MCs are crucial for the induction of protective innate immune responses to bacterial skin infections...
  95. ncbi Colophony-induced contact dermatitis due to ECG electrodes in an infant
    Elsbeth Oestmann
    Allergie-Centrum-Charit, , Venerologie und Allergologie, , Berlin, Germany
    Contact Dermatitis 56:177-8. 2007
  96. ncbi Bivalent effect of UV light on human skin mast cells-low-level mediator release at baseline but potent suppression upon mast cell triggering
    Sven Guhl
    Department of Dermatology and Allergy, , Schumannstr. 20/21, D-10117 Berlin, Germany
    J Invest Dermatol 124:453-6. 2005
    ..Immunosuppressive effects predominate in activated MC, thus corresponding with the beneficial effects in inflammatory diseases, whereas in resting MC, both stimulatory and inhibitory effects are observed...
  97. ncbi Urticaria
    T Zuberbier
    Department of Dermatology and Allergy, University Hospital Charit, Humboldt University, Berlin, Germany
    Allergy 58:1224-34. 2003
    ..g. allergic rhinitis. Alternative treatments should be reserved for unresponsive patients...
  98. ncbi 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells
    Guido Heine
    Allergy Center Charité, CCM, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany
    Eur J Immunol 38:2210-8. 2008
    ....
  99. ncbi Allergological approach to drug hypersensitivity reactions
    Bernhard Przybilla
    , , Germany
    J Dtsch Dermatol Ges 6:240-3. 2008
  100. ncbi Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report
    Cezmi A Akdis
    Swiss Institute of Allergy and Asthma Research, Davos
    J Allergy Clin Immunol 118:152-69. 2006
    ..The consensus report is part of the PRACTALL initiative, which is endorsed by both academies...
  101. ncbi [Therapy of atopic eczema with calcineurin inhibitors]
    Thomas A Luger
    Hautklinik, , Deutschland
    J Dtsch Dermatol Ges 3:385-91. 2005